- Lung Cancer Research
- Radiation Therapy Research
- Immunity Research
Welsh and his team are committed to finding new therapies for combating solid thoracic tumors, particularly lung cancers. Their research focuses on reactivating the immune system with radiation in order to battle not just the tumor site, but the microenvironment that it creates. Through a reactivation of the immune system with radiation the Welsh Laboratory hypothesizes that this is the key to suppressing local and distant disease, which could have applications in not just lung cancer, but other solid tumors such as breast, prostrate and pancreatic. An application of radiation to a solid tumor type stimulates antigen presentation allowing T-cells in the body to attack the cancer.
The Welsh Laboratory understands the global impact of these solid tumor cancers and aims to bring cost-efficient, easily applicable, and high results yielding therapies to the rest of the world. While, the Welsh lab has a particular focus on lung cancer all of their current research efforts will benefit a wide array of solid tumors. The Welsh Laboratory's goal is to pioneer combinatory immunotherapy and radiation to create a systemic treatment for all types of metastatic disease.
A diagnosis of cancer greatly impacts a patient’s life and his or her loved ones. Welsh and his team are discovering new pathways for immunotherapy checkpoints, investigating molecular targets, and running clinical trials combining concurrent radiation with recently FDA approved immunotherapy drugs, such as Ipilimumab and Nivolumab.
Welsh and his team are conducting exciting research that is causing a paradigm shift in the way scientists and physicians view radiation therapy. Not only does the Welsh team see the potential of radiation therapy as a form of localized tumor control, but also its potential for reactivating the immune system to serve as an in situ vaccine that promotes anti-tumor immunity. With this in mind, the Welsh Laboratory investigates the phenomenon known as the abscopal effect, in which radiation administered locally can also promote distant sites of non-irradiated tumors to respond.
Can the power of radiation be harnessed to also treat systemic cancers? What is the optimal set of conditions that create a reproducible abscopal effect in every patient with thoracic malignancies? These are some of the questions that Welsh and his team are working to answer.